Vasorelaxant effect of a newly synthesized dihydropyridine ethyl ester (DHPEE) on rat thoracic aorta: Dual mechanism of action

Advanced Pharmaceutical Bulletin

Volumn 1, Issue 1, 2011, Pages 10-17

  Babaei, Hossein ^a,b   Ebrahimi, Farzaneh ^a,b   Mojarrad, Javid Shahbazi ^b   Azarmi, Yadollah ^b   Gharehbagheri, Afsaneh ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Angiotensin II; Angiotensin receptor blocker; Calcium channel blocker; Dhpee; Rat aorta

Indexed keywords

ANGIOTENSIN RECEPTOR; CALCIUM; CALCIUM CHANNEL L TYPE; DIHYDROPYRIDINE DERIVATIVE; DIHYDROPYRIDINE ETHYL ESTER; LOSARTAN; NIFEDIPINE; PENTOBARBITAL; UNCLASSIFIED DRUG;

ANIMAL TISSUE; AORTA MEDIA; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; FEMALE; IN VITRO STUDY; MALE; MEMBRANE DEPOLARIZATION; NONHUMAN; PATIENT COMPLIANCE; RAT; THORACIC AORTA; VASODILATATION;

EID: 84875912385     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.5681/apb.2011.002     Document Type: Article

References (40)

1. Wolfgang W, Michael E, Jacobus, CA, Joachim S, Ulrich B. A review on Telmisartan:A novel, Long acting Angiotensin II-receptor Antagonist. Cardiovas Drug Rev2000; 18: 127-154.
2. Brunner HR, Nussberger J, Wäber B. Angiotensin Antagonists. In: Robertson JIS, Nicholls MG, Editors.The Renin Angiotensin System.London:Gower Medical Publishing, 1993; 86(14): p: 1-86.
3. Frank GD, Eguchi S. Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal 2003; 5: 771-780.
4. Failli P, Alfaran C, Franchi S, et al. Losartan counteracts the hyper-reactivity to angiotensin II and ROCKI over-activation in aorta isolated from streptozotocin-injected diabetic rats. Cardiovascular Diabetology2009; 8: 32-45.
5. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation.Physiol Rev 1996; 76: 425-536.
6. Carmines PK. Segment-specific effect of chloride channel blockade on rat renal arteriolar contractile responses to angiotensin II. Am J Hypertens1995; 8: 90-94.
7. Jensen BL, Skott O. Blockade of chloride channels by DIDS stimulates renin release and inhibits contraction of afferent arterioles. AM J Physiol 1996, 271: F718-727.
8. 2+ - activated Cl-conductance in smooth muscle. Am J Physiol 2005; 271: C435-545.
9. Steendahl J, Holestain-Rathlou NH, Sorensen CM, Salomonsson M. Effects of chloride channel blockers on rat renal vascular responses to angiotensin II and norepinephrine. Am J Physiol Renal Physiol2004; 286: F323-330.
10. Hadizadeh F, Imenshahi M, Esmaili P, Taghiabedi M. Synthesis and Effects of NovalDihyropyridines as Dual calcium channel blocker and Angiotensin Antagonist on isolated rat aorta. Iranian Journal of Basic Medicinal Sciences2010; 13:P195-201.
11. European society of hypertension-european society of cardiology guidelines committee. 2003 european society of hypertension-european society of cardiology guidelines for the management of arterial hypertension. jhypertens2003; 21: 1011-1053.
12. Singh RK, Barker S. Progress in the development of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.Curr Opin Investig Drugs2005; 6: 269-74.
13. Triggle DJ. The 1,4-dihydropyridine nucleus: a pharmacophoric template part 1. Actions at ion channels. Mini Rev Med Chem 2003;3: 215-23.
14. Godfriend T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986; 38: 321-416.
15. Taira N. Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987; 59: 24B-29B.
16. Frank J. Managing hypertension using combination therapy.Am Fam Physician2008; 77: 1279-1286.
17. Mancia G, Seravalle G, Grassi G. Tolerability and treatment compliance with angiotensin II receptor antagonists. Am J Hypertens 2003; 16: 1066-1073
18. Shahbazi-Mojarrad J, Nazemiyeh H, Kaviani F. Synthesis and Regioselective Hydrolysis of NovalDiallcyl 4-imidazolyl-1,4-Dihydropyridine-3,5-dicarboxylate as potential dual acting Angiotensin II inhibitor and calcium channel blockers. J Iran ChemSoc2010; 7: 171-179.
19. Xia-li WV, Yin W, Gheng J, Zhao YY. Calcium channel blocking activity of calycosin, a major active component of Astragali Radix, on rat aorta. Acta Pharmacologica Sinica 2006; 27: 1007- 1012
20. Guo XZ, Shi L, Wang R, Liu XX, Li BG, Lu XX. Synthesis and biological activities of novel nonpeptide angiotensin II receptor antagonists based on benzimidazole derivatives bearing a heterocyclic ring. Bioorg Med Chem 2008; 16: 10301-10310.
21. Toda N, Ayajiki K, Okamura T. Interaction of endothelial nitric oxide and angiotensin in the circulation. Pharmacol Rev 2007; 59: 54-87.
22. Ishimitsu T, Numabe A, Masuda T, et al. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension. Hypertens Res 2009; 32: 962-968.
23. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich) 2008; 10: 27-32.
24. Babaei H, Sadeghpour O, Nahar L, et al. Antioxidant and Vasorelaxant Activities of Flavonoids from Amygdaluslycioides var. horrid. Turkish Journal of Biological Sciences 2008; 32: 203-208
25. Azarmi Y, Mohammdi A, Babaei H. Role of endothelium on relaxant effect of geraniol in isolated rat aorta. Pharmaceutical Sciences 2009; 14: 311-319
26. Babaei H, Azarmi Y. 17β-Estradiol inhibits calcium dependent and independent contractions in isolated human saphenous vein. Steroids 2008; 73: 844-850
27. Salomonsson M, Sorensen CM, Arend shorts WJ, Steendahl J, Holstein-Rathlou NH. Calcium handling in afferent arterioles. Acta Physiol Scand 2004; 181: 421-429.
28. Beigly S, Ghiaee S, Ebrahimi SA, Mahmoudian M.Effects of mebudipine and dibudipine, two new calcium channel blocker, on guinea-pig isolated common bile duct. Acta Physiologica Hungarica 2004; 91:111-118.
29. Failli P, Alfarano C, Franchi-Micheli S, Mannucci E, Cerbai E. Losartan counteracts the hyper-reactivity to angiotensin II and ROKI over-activation in aortas isolated from streptozocin-injected diabetic rats. J Cardiovascular Diabetology 2009; 8: 32-45.
30. Arendshorst WJ, Brann storm K, Ruan X. Actions of angiotensin II on the renal microvasculature. J Am Soc Nephrol 1999; 10: S149-61.
31. Inone K, Nishimura H, Kubota J, Kitaura Y. Nitric oxide mediates inhibitory effect of losartan on angiotensin-induced contractions in hamster but not rat aorta. J ReninAngiotensinAldostroneSyst 2000; 1: 180-3.
32. Webb RC. Smooth muscle contraction and relaxation. Adv Physiol Educ 2003; 27: 201-206.
33. Karaki H, Ozaki H, Hori M, Mitsui-Saito M, Amano KI, Harada KI. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997; 49: 157-215.
34. Savineau JP, Marthan R. Cytosolic calcium oscillations in smooth muscle cells. News physiolSci 2000; 15: 50-55.
35. Benham CD, Bolton TB, Lang RJ, Takewaki T. Calcium activated potassium channels in single smooth muscle cells of rabbit jejunum and guinea-pig mesenteric artery. J Physiol1986; 371: 45- 67.
36. Karaki H, Ozaki H, Hori M, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997; 49: 157-215.
37. Ruan X, Arendshorst WJ. Calcium entry and mobilization signaling pathways in Ang II-induced renal vasoconstriction in vivo. Am J Physiol 1996; 270: F398-F405.
38. Hun Do K, Kim MS, Kim JH, et al. Angiotensin II-induced aortic ring constriction is mediated by phosphatidylinositol 3-kinase/L-type calcium channel signaling pathway. Experimental and Molecular Medicine 2009; 41: 569-576.
39. Motohiko C, Tsoyoshi O, Naoyoki H, Yoichiro N, Hisashi S. Pharmacological and clinical profile of telmisartan, a celective angiotensin II type 1 receptor blocker. NipponYakurigaku Zassi 2004; 124: 31-39.
40. Wolfgang W, Michael E, Jacobus CA, Joachim S, Ulrich B, Thomas E. A review on Telmisartan: A novel, Long acting Angiotensin II-receptor Antagonist. Cardiovascular Drug Reviews 2009; 18: 127-154.